TB-500: The Single Ingredient Behind Two Popular Blends

The short version

TB-500 is a lab-made, seven-amino-acid piece (Ac-LKKTETQ) of a much larger natural protein your body already makes, called thymosin beta-4. Think of thymosin beta-4 as a foreman that keeps a stockpile of a building-block protein (actin) ready to go, so the moment a construction crew shows up at a damaged site, it can quickly change shape and move cells into place. TB-500 is meant to be a small, injectable stand-in that carries just the piece of the foreman responsible for grabbing that building block.

Most of the encouraging animal research on this mechanism was actually done with the full-length foreman protein, not the small fragment sold as TB-500 — an identity distinction this page flags throughout. TB-500 is also the shared ingredient behind both GLOW (research blend) and KLOW, the two multi-peptide blends covered elsewhere on this site. It has no FDA-approved use and is not intended for human consumption.

What it is

TB-500 is the common commercial and research name for the synthetic, N-acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH — residues 17 through 23 of the 43-amino-acid protein thymosin beta-4 (gene name TMSB4X). That short stretch, LKKTETQ, is the region of the protein responsible for grabbing onto actin, the structural protein that gives cells their shape and lets them move.

This is an important distinction the research literature is explicit about: 'TB-500' in commerce and in anti-doping science refers to this small 7-amino-acid fragment (about 889 daltons), but the large majority of published efficacy research — the wound-healing, stroke and cardiac studies — was done using the full-length, 43-amino-acid thymosin beta-4 protein (about 4,963 daltons), not the fragment. Whether the small fragment reproduces the parent protein's effects at the concentrations used in peptide research has not been established in controlled human trials. This page flags that distinction wherever it applies.

How it works

Full-length thymosin beta-4 is the cell's main reservoir-keeper for actin, the protein that builds a cell's internal scaffolding. It binds one actin molecule at a time and caps both ends, holding a buffered pool of 'ready' actin in reserve rather than letting it lock into permanent structures. When a cell needs to change shape quickly — to crawl toward an injury, for instance — that reserve pool lets it respond fast.

The LKKTETQ fragment that makes up TB-500 is the specific piece of the protein that does this actin-grabbing. In injury models, full-length thymosin beta-4 (and, by extension, its actin-binding region) is associated with faster cell migration, new blood-vessel growth, reduced inflammation and programmed cell death, less scar-forming tissue, and recruitment of repair cells to the site — a broad, foreman-like coordinating role rather than a single narrow effect.

Whether the isolated seven-amino-acid fragment reproduces all of that at typical research doses is the open question that runs through the whole page: the mechanism is well characterized for the full protein, less so for the small piece sold commercially.

What the research shows

The same 2026 Sports Medicine review anchors this page too: it names TB-500/thymosin beta-4 among unapproved peptides that show favorable repair outcomes in animal models, while cautioning that rigorous human safety data are scarce and that real harm is possible outside regulatory oversight ^[1].

Directly relevant animal work: in rats given an artificial stroke, thymosin beta-4 injected starting 24 hours later improved neurological recovery at two of three tested doses, with benefits lasting from day 14 through day 56 — but the highest dose tested gave no extra benefit, showing that more is not automatically better ^[11]. A widely cited review consolidates thymosin beta-4's mechanism across models: actin binding, faster cell migration, reduced scar-forming cells, anti-inflammatory and anti-cell-death signaling, and promotion of new blood-vessel growth — the basis for clinical trials in skin wounds, corneal injury, and heart and nervous-system repair ^[12].

On the human side, a randomized, placebo-controlled Phase 1 study gave 40 healthy volunteers intravenous synthetic thymosin beta-4 daily for two weeks at doses up to 1,260 mg; it was well tolerated, with only infrequent mild-to-moderate side effects and no serious safety concerns ^[13]. And at the structural level, X-ray crystallography confirmed exactly how the protein grabs actin — one molecule at a time, capping both ends to prevent it from assembling — the physical basis for the whole mechanism ^[14]. All four studies used the full-length protein, not the small TB-500 fragment.

Reported effects, cautions & safety

People using TB-500 in research communities describe a fairly consistent profile, drawn from forum discussion, community write-ups and supplier review pages. This is anecdotal, not clinical evidence — TB-500 as a fragment has essentially no completed controlled human trials behind it, and no report below comes with a verified dose.

Reported benefits: faster-feeling recovery from tendon, ligament and muscle injuries is by far the most common reason people say they use it. Less joint pain and stiffness with better range of motion, improved overall flexibility, a calmer, less-inflamed feeling after workouts, better wound and skin healing, and occasionally more hair growth are also described.

Reported adverse effects: injection-site redness, swelling or aching is the single most common complaint, typically mild and gone within a day or two. Temporary tiredness or lethargy, especially early on, is also frequently mentioned, along with occasional head rush or headache, a brief flu-like feeling, rare nausea, and a heightened awareness of an existing injury in the first week or two.

Cited cautions: human safety for the TB-500 fragment specifically is essentially unstudied, and the 2026 review of unapproved peptides makes that gap explicit for the category as a whole ^[1][13]. TB-500 is banned in competitive sport at all times under WADA rules, with anti-doping labs able to detect it and its breakdown products ^[1]. It's worth remembering TB-500 is only the small fragment of thymosin beta-4, not the full protein most of the encouraging research used — so felt effects could reasonably be smaller or different than the full-protein studies suggest ^[12]. Research-grade material also is not made to medicine-grade standards, so identity and purity can vary between suppliers, adding an unpredictable layer on top of the biology itself.

Where it fits in Recovery & Tissue Repair

TB-500 is the single ingredient this whole desk is organized around. On its own, it represents one clearly defined mechanism — actin-binding and cell migration — inherited from a natural repair protein. In GLOW (research blend), it's paired with a skin-focused copper peptide and a vascular-healing peptide; in KLOW, that same trio gains a fourth, anti-inflammatory ingredient. Reading TB-500 on its own first is the clearest way to understand what it's actually thought to contribute before the blends layer three or four mechanisms on top of it. See the comparison page for how all three compare directly.